Table 1 Clinical and laboratory features of patients with EOLVV

Age at onset, years, mean ± SD

67.8 ± 8.6

62.9 ± 10.6

0.12

73.5 ± 9.2

0.10

Female, n (%)

9/11 (81.8)

14/16 (87.5)

1

8/13 (61.5)

0.39

Positive temporal artery findings, n (%)

0/11 (0)

0/16 (0)

13/13 (100)

PMR diagnosed, n (%)

11/11 (100)

0/16 (0)

6/13 (46.2)

Jaw claudication, n (%)

3/11 (27.3)

0/12 (0)

0.09

2/11 (18.2)

1

Newly diagnosed and untreated patients, n

11/11

10/16

11/13

 aPL, n (%)

3/7 (42.9)

0/7 (0)

0.19

4/6 (66.7)

0.59

 HLA-B52, n (%)

6/7 (85.7)

3/10 (30.0)

0.0498

4/6 (66.7)

0.56

 HLA-DR4, n (%)

2/7 (28.6)

3/8 (37.5)

1

2/5 (40)

1

 CRP, mg/dl

9.0 (2.6–13.6)

4.4 (1.04–17.4)

0.65

7.5 (4.9–9.9)

0.95

 ESR, mm/h

108 (96–116.5)

79.1 (53.8–91.2)

< 0.01

89.7 (81.8–102.3)

0.09

 Platelet count, × 10⁴ cells/μl

47.8 (42.3–54.4)

29.4 (17.6–32.0)

< 0.01

40.3 (29.9–51.1)

0.21